Health-economic burden of Parkinson's disease in Portugal: A cohort study;Estudio de cohortes sobre la carga socioeconómica de la enfermedad de Parkinson en Portugal

Revista de Neurologia

Volumn 52, Issue 5, 2011, Pages 264-274

  Reese, Jens P ^a   Winter, Yaroslav ^a   Rosa, Mario M ^c   Rodrigues E Silva, Antonio M ^a   Von Campenhausen, Sonja ^a,b   Freire, Rita ^c   Mateus, Céu ^c   Balzer Geldsetzer, Monika ^a   Bötzel, Kai ^b   Oertel, Wolfgang H ^a   Dodel, Richard ^a   Sampaio, Cristina ^d  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^d Universidad Médica de Lisboa   (Portugal)

Author keywords

Cost; Economic burden; Parkinson's disease; Portugal

Indexed keywords

ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG COST; ECONOMIC ASPECT; HEALTH CARE COST; HOSPITALIZATION; HUMAN; PARKINSON DISEASE; PORTUGAL; QUALITY OF LIFE; RATING SCALE;

EID: 79952332709     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5205.2010492     Document Type: Article

References (42)

1. Lindgren P, Von Campenhausen S, Spottke AE, Siebert U, Dodel R. Cost of Parkinson's disease in Europe. Eur J Neurol 2005; 12 (Suppl 1): S68-73.
2. Winter Y, Bezdolnyy Y, Katunina E, Avakjan G, Reese JP, Klotsche J, et al. Incidence of Parkinson's disease and atypical Parkinsonism: Russian population-based study. Mov Disord 2010; 25: 349-56.
3. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Costs of disorders of the brain in Europe. Eur J Neurol 2005; 12 (Suppl 1): S1-27.
4. Marco-Llorente J, Rojo-Martínez E. Otros trastornos no motores en la enfermedad de Parkinson. Rev Neurol 2010; 50 (Supl 2): S75-83.
5. Durán-Ferreras E, Chacón JR. Tratamiento de la psicosis parkinsoniana. Rev Neurol 2009; 48: 645-53.
6. Santangelo G, Vitale C, Trojano L, Longo K, Cozzolino A, Grossi D, et al. Relationship between depression and cognitive dysfunctions in Parkinson's disease without dementia. J Neurol 2009; 256: 632-8.
7. LePen C, Wait S, Moutard-Martin F, Dujardin M, Ziegler M. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999; 16: 59-69. (Pubitemid 29330472)
8. Von Campenhausen S, Winter Y, Gasser J, Seppi K, Reese JP, Pfeiffer KP, et al. Cost of illness and health services patterns in Morbus Parkinson in Austria. Wien Klin Wochenschr 2009; 121: 574-82.
9. Reese JP, Winter Y, Balzer-Geldsetzer M, Botzel K, Eggert K, Oertel WH, et al. Parkinson's disease: cost-of-illness in an outpatient cohort. Gesundheitswesen 2011; 73: 22-9.
10. Spottke AE, Reuter M, Machat O, Bornschein B, Von Campenhausen S, Berger K, et al. Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics 2005; 23: 817-36. (Pubitemid 41420428)
11. Winter Y, Von Campenhausen S, Brozova H, Skoupa J, Reese JP, Botzel K, et al. Costs of Parkinson's disease in Eastern Europe: a Czech cohort study. Parkinsonism Relat Disord 2010; 16: 51-6.
12. Winter Y, Von Campenhausen S, Popov G, Reese JP, Klotsche J, Botzel K, et al. Costs of illness in a Russian cohort of patients with Parkinson's disease. Pharmacoeconomics 2009; 27: 571-84.
13. Abasolo-Osinaga E, Abecia-Inchaurregui LC, Fernández-Díaz E, Barcenilla-Laguna A, Banares-Onraita T. Prevalencia y coste farmacológico de la enfermedad de Parkinson en España. Rev Neurol 2006; 43: 641-5. (Pubitemid 47573965)
14. Cubo E, Martínez-Martín P, González M, Frades B. Impact of motor and non-motor symptoms on the direct costs of Parkinson's disease. Neurologia 2009; 24: 15-23.
15. Winter Y, Von Campenhausen S, Reese JP, Balzer-Geldsetzer M, Longo K, Spiga G, et al. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study. Neurodegener Dis 2010; 7: 365-72.
16. Gibb WRG. Accuracy in the clinical diagnosis of parkinsonian syndromes. Postgrad Med J 1988; 64: 345-512.
17. Park A, Stacy M. Non-motor symptoms in Parkinson's disease. J Neurol 2009; 256: 293-8.
18. Hoehn MM, Yahr M. Parkinsonism: onset, progression and mortality. Neurology 1967; 5: 427-42.
19. Martínez-Martín P, Gil-Nagel A, Gracia LM, Gómez JB, Martínez-Sarries J, Bermejo F. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord 1994; 9: 76-83. (Pubitemid 24022618)
20. Greiner W, Claes C, Busschbach JJ, Graf von der Schulenburg JM. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ 2005; 6: 124-30. (Pubitemid 40905009)
21. Schrag A, Selai C, Jahanshani M, Quinn N. The EQ-5D -a generic quality of life measure- is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2000; 69: 67-73. (Pubitemid 30410417)
22. Bentes M, Matias-Dias C, Sakellarides C, Bankauskaite V. Health care systems in transition. Copenhagen: WHO Regional Office for Europe on behalf of the European Observatory on Health Systems and Policies; 2004.
23. Aarsland D, Bronnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U, et al. The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 2009; 80: 928-30.
24. Portaria a110/2007 (drg version: Ap-drg 21), Portuguese Ministry of Health; 2007, Portaria A110/2007, pp 2-124.
25. Catalogue of the medical goods company 'Bastos viegas'. URL: http://www.bastosviegas.com. [25.11.2008].
26. Gold MR, Siegel JE, Russell LB, Weinstein MC. Costeffectiveness in health and medicine. New York: Oxford University Press; 1996.
27. INE. Ministério do Trabalho e da Solidariedade Social: ganho médio mensal (€) por sexo e actividade económica. Lisboa: Instituto Nacional de Estatística de Portugal; 2005.
28. Efron B, Tibshirani RJ. An introduction to the bootstrap. London: Chapman & Hall; 1993.
29. Whetten-Goldstein K, Sloan F, Kulas E, Cutson T, Schenkman M. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 1997; 45: 844-9. (Pubitemid 27289932)
30. Hagell P, Nordling S, Reimer J, Grabowski M, Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson's disease. Mov Disord 2002; 17: 1213-20. (Pubitemid 36041335)
31. Keranen T, Kaakkola S, Sotaniemi K. Economic burden and quality of life impairment increase with severity of PD. Parkinsonism Relat Disord 2003; 9: 163-8. (Pubitemid 36173566)
32. Findley L, Aujla M, Bain PG, Baker M, Beech C, Bowman C, et al. Direct economic impact of Parkinson's disease: a research survey in the United Kingdom. Mov Disord 2003; 18: 1139-45.
33. Winter Y, Balzer-Geldsetzer M, Von Campenhausen S, Spottke A, Eggert K, Oertel WH, et al. Trends in resource utilization for Parkinson's disease in Germany. J Neurol Sci 2010; 294: 18-22.
34. Dodel RC, Eggert KM, Singer MS, Eichhorn TE, Pogarell O, Oertel WH. Costs of drug treatment in Parkinson's disease. Mov Disord 1998; 13: 249-54. (Pubitemid 28127799)
35. Winter Y, Balzer-Geldsetzer M, Spottke A, Reese JP, Baum E, Klotsche J, et al. Longitudinal study of the socioeconomic burden of Parkinson's disease in Germany. Eur J Neurol 2010; 17: 1156-63.
36. McCrone P, Allcock LM, Burn DJ. Predicting the cost of Parkinson's disease. Mov Disord 2007; 22: 804-12. (Pubitemid 46800101)
37. Konig HH, Bernert S, Angermeyer MC, Matschinger H, Martinez M, Vilagut G, et al. Comparison of population health status in six European countries: results of a representative survey using the EQ-5D questionnaire. Med Care 2009; 47: 255-61.
38. Badia X, Schiaffino A, Alonso J, Herdman M. Using the Euroqoi 5-D in the Catalan general population: FEASIBILITY and construct validity. Qual Life Res 1998; 7: 311-22. (Pubitemid 28207020)
39. Winter Y, Von Campenhausen S, Gasser J, Seppi K, Reese JP, Pfeiffer KP, et al. Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study. J Neurol 2010; 257: 638-45.
40. Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, et al. Treatment of early Parkinson's disease. Part 1. Eur Neurol 2009; 61: 193-205.
41. Catalogue of home care agency 'Prosavos'. Vila do conde. Portugal. 2007/08; 2008.
42. INFARMED. Prontuário terapêutico, Portugese Ministry of Health; 2008.